Avita Medical (RCEL)
(Real Time Quote from BATS)
$8.31 USD
-0.26 (-3.03%)
Updated Apr 25, 2024 01:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Avita Medical Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 50 | 34 | 14 | 29 | 14 |
Cost Of Goods | 8 | 6 | 2 | 6 | 3 |
Gross Profit | 42 | 28 | 12 | 23 | 11 |
Selling & Adminstrative & Depr. & Amort Expenses | 77 | 55 | 26 | 50 | 53 |
Income After Depreciation & Amortization | -34 | -27 | -14 | -27 | -42 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 1 | 0 | 0 | 0 | 0 |
Pretax Income | -35 | -27 | -14 | -27 | -42 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -35 | -27 | -14 | -27 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -35 | -27 | -14 | -27 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | -26 | -14 | -26 | -42 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 1 | 0 |
Income After Depreciation & Amortization | -34 | -27 | -14 | -27 | -42 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 25.33 | 25.00 | 22.67 | 20.29 | 12.68 |
Diluted EPS Before Non-Recurring Items | -1.40 | -1.07 | -1.17 | -2.07 | -1.95 |
Diluted Net EPS (GAAP) | -27.93 | -21.33 | -1.17 | -23.45 | -41.41 |
Fiscal Year end for Avita Medical Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 14.20 | 13.65 | 11.75 | 10.55 |
Cost Of Goods | NA | 1.80 | 2.11 | 2.20 | 1.67 |
Gross Profit | NA | 12.40 | 11.53 | 9.55 | 8.88 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 18.33 | 20.22 | 19.92 | 18.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.93 | -8.69 | -10.37 | -9.19 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 1.12 | 0.01 | 0.01 | 0.00 |
Pretax Income | NA | -7.05 | -8.70 | -10.37 | -9.19 |
Income Taxes | NA | 0.01 | 0.01 | 0.01 | 0.03 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.07 | -8.71 | -10.38 | -9.22 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.07 | -8.71 | -10.38 | -9.22 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 25.48 | 25.40 | 25.24 | 25.20 |
Diluted EPS Before Non-Recurring Items | NA | -0.28 | -0.34 | -0.41 | -0.37 |
Diluted Net EPS (GAAP) | NA | -5.53 | -6.80 | -8.20 | -7.40 |